Is Design Therapeutics, Inc. (DSGN) a Buy, Sell, or Hold?
Design Therapeutics, Inc.
NASDAQ:DSGN
$13.67 USD
-$0.18 (-1.34%)
- Volume
- 582.41K
- Average Volume
- 979.66K
- Market Capitalization
- $853.79M
- P/E Ratio
- -11.39
- Dividend Yield
- 0.00%
- Price Target
- $20.50
- Year High
- $17.25
- Year Low
- $3.76
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.28
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Pratik Shah |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DSGN |
| CUSIP | 25056L103 |
| CIK | 0001807120 |
| Web | https://www.designtx.com |
| Phone | 858 293 4900 |
| Currency | USD |
| Employees | 124 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 22.28 |
| Quick Ratio | 22.28 |
| Cash Ratio | 1.25 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.88 |
| Price / Cash Flow | -15.78 |
| Price / Book | 3.85 |
Price Target and Rating
| Average Stock Price Forecast | $20.50 |
| High Stock Price Forecast | $21.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -33.32% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.22 |
| Trailing P/E Ratio | -11.39 |
| PEG Ratio | 0.59 |
| P/E Growth | 0.59 |
| Net Income | $-69.79M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -33.07% |
| Return on Assets | -30.25% |
Financials Score
| AltmanZ Score | 40.13 |
| Piotroski Score | 1.00 |
| Working Capital | 216.86M |
| Total Assets | 230.44M |
| Ebit | -69.71M |
| Market Cap | 865.34M |
| Total Liabilities | 12.39M |
Poll Results
About Design Therapeutics, Inc. (NASDAQ:DSGN) Stock
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions ... caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
2026-06-30 08:00:00
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1).
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
2026-06-24 18:07:55
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-28 08:00:00
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
2026-05-18 14:26:20
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.
2026-05-18 11:00:50
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
2026-05-18 07:00:00
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing
2026-05-17 16:00:00
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
2026-05-17 16:00:00
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026.
Frequently Asked Questions
-
What is the current Design Therapeutics, Inc. (DSGN) stock price?
-
Design Therapeutics, Inc.(NASDAQ:DSGN) stock price is $13.67 in the last trading session. During the trading session, DSGN stock reached the peak price of $17.25 while $3.76 was the lowest point it dropped to. The percentage change in DSGN stock occurred in the recent session was --1.34% while the dollar amount for the price change in DSGN stock was -$-0.18.
-
DSGN's industry and sector of operation?
-
The NASDAQ listed DSGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DSGN?
-
Aseem Z. Ansari | Co-Founder & Scientific Advisor
Julie D. Burgess | Chief Accounting Officer
Doane Chilcoat | Chief Technology Officer
Jim Kerr | Chief of Manufacturing & Product Development
Sean Jeffries | Chief Operating Officer -
How many employees does DSGN have?
-
Number of DSGN employees currently stands at 124. DSGN operates from 6005 Hidden Valley Road, Carlsbad, CA 92011, US.
-
Link for DSGN official website?
-
Official Website of DSGN is: https://www.designtx.com
-
How do I contact DSGN?
-
DSGN could be contacted at phone #858 293 4900 and can also be accessed through its website. DSGN operates from 6005 Hidden Valley Road, Carlsbad, CA 92011, US.
-
How many shares of DSGN are traded daily?
-
The average number of DSGN shares traded daily for last 3 months was 979.66K.
-
What is the market cap of DSGN currently?
-
The market value of DSGN currently stands at $853.79M with its latest stock price at $13.67